论文部分内容阅读
目的观察培菲康联合不同药物治疗溃疡性结肠炎(UC)的临床效果并探讨其作用机制。方法将135例 UC患者随机分为观察组、对照1组和对照2组各45例，观察组给予培菲康联合美沙拉嗪治疗，对照1组给予培菲康联合柳氮磺吡啶，对照2组单纯给予美沙拉嗪；用药8周后观察三组患者的临床总有效率及不良反应情况，采用酶联免疫吸附(ELISA)测定血清核因子-κB (NF-κB)、肿瘤坏死因子-α(TNF-α)的水平变化。结果观察组临床总有效率为97.78%，明显优于对照1组的79.55%和对照2组的73.33%(P<0.05)；三组患者的NF-κB、TNF-α水平均较治疗前有所下降(P<0.05或P<0.01)，且观察组TNF-α的下降明显优于对照1组和对照2组(P0.05)。结论培菲康联合美沙拉嗪治疗 UC 安全有效，其作用可能与调节 NF-κB、TNF-α的水平变化有关。“,”Obj ective]To observe the clinical efficacy and mechanism of Bifico combined with different drugs for the treatment of ulcerative colitis(UC).[Methods]Totally 135 patients with UC were randomly divided into observation group and control group 1 and control group 2 with 45 patients in each group.The treatment group was given bifico combined with mesalazine.The control group 1 was given bifico combined with sulfasalazine, while the control group 2 was given mesalazine alone.The total clinical effective rate and adverse reaction of 3 groups 8 weeks after treatment were observed.Serum levels of nuclear factor-κB(NF-κB)and tumor necrosis fac-tor-alpha(TNF-α)were determined by enzyme linked immunosorbent assay(ELISA).[Results]The total effective rate of observation group was 97.78%,which was significantly better than those in control group 1(79.55%)and control group 2(73.33%)(P <0.05).Compared with before treatment,the levels of NF-κB and TNF-αin 3 groups after treatment were decreased(P<0.05 orP<0.01),and the decline of TNF-αin observation group was obviously better than control group 1 and control group 2(P 0.05).[Conclusion]Bifico combined mesalazine for the treat-ment of UC is safe and effective,which may be related to the regulation of NF-κB and TNF-α.